Interleukin-27 early impacts Leishmania infantum infection in mice and correlates with active visceral disease in humans

dc.contributor.authorPérez-Cabezas, Begoñapor
dc.contributor.authorCecílio, Pedropor
dc.contributor.authorRobalo, Ana Luísapor
dc.contributor.authorSilvestre, Ricardo Jorge Lealpor
dc.contributor.authorCarrillo, Eugeniapor
dc.contributor.authorMoreno, Javierpor
dc.contributor.authorMartín, Juan V. Sanpor
dc.contributor.authorVasconcellos, Ritapor
dc.contributor.authorSilva, Anabela Cordeiro dapor
dc.date.accessioned2017-03-03T17:24:23Z
dc.date.available2017-03-03T17:24:23Z
dc.date.issued2016-11
dc.date.submitted2016-09
dc.date.updated2017-02-14T10:48:04Z
dc.description.abstractThe complexity of Leishmania host interactions, one of the main leishmaniasis issues, is yet to be fully understood. We detected elevated IL-27 plasma levels in European patients with active visceral disease caused by Leishmania infantum, which returned to basal levels after successful treatment, suggesting this cytokine as a probable infection mediator. We further addressed this hypothesis recurring to two classical susceptible visceral leishmaniasis mouse models. BALB/c, but not C57BU6 mice, showed increased IL-27 systemic levels after infection, which was associated with an upregulation of IL-27p28 expression by dendritic cells and higher parasite burdens. Neutralization of IL-27 in acutely infected BALB/c led to decreased parasite burdens and a transient increase in IFN-gamma(+) splenic T cells, while administration of IL-27 to C57BU6 promoted a local anti-inflammatory cytokine response at the site of infection and increased parasite loads. Overall, we show that, as in humans, BALB/c IL-27 systemic levels are infection dependently upregulated and may favor parasite installation by controlling inflammation.por
dc.description.sponsorshipFundação para a Ciência e Tecnologia (FCT)/Ministério da Educação e da Ciência (MEC), co-funded by FEDER under the PT2020 Partnership Agreement through the Research Unit NO. 4293; by European Community’s Seventh Framework Programme under grant agreement No. 603182 (Project MuLeVaClin) and by the ISCIII-AES project (project reference PI13/00440). PC and BP-C are supported by fellowships from the European Community’s Seventh Framework Programme under grant agreements No. 603182 (Project MuLeVaClin) and No. 603240-2 (Project NMTryPI)por
dc.distributioninternationalpor
dc.identifier.citationPérez-Cabezas, B., Cecílio, P., Robalo, A. L., Silvestre, R., Carrillo, et. al.(2016). interleukin-27 early impacts Leishmania infantum infection in Mice and correlates with active Visceral Disease in humans. Frontiers in Immunology, 7por
dc.identifier.doi10.3389/fimmu.2016.00478por
dc.identifier.issn1664-3224por
dc.identifier.urihttps://hdl.handle.net/1822/44896
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherFrontiers Mediapor
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/603181/EU
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/603240/EU
dc.relation.publisherversionhttp://journal.frontiersin.org/article/10.3389/fimmu.2016.00478/fullpor
dc.rightsopenAccesspor
dc.subjectIL-27por
dc.subjectLeishmania infantumpor
dc.subjectHumanpor
dc.subjectMouse modelspor
dc.subjectImmune regulationpor
dc.subject.fosCiências Médicas::Medicina Básicapor
dc.subject.wosScience & Technologypor
dc.titleInterleukin-27 early impacts Leishmania infantum infection in mice and correlates with active visceral disease in humanspor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationEndPage12por
oaire.citationIssueNOVpor
oaire.citationStartPage1por
oaire.citationTitleFrontiers in Immunologypor
oaire.citationVolume7por
sdum.journalFrontiers in Immunologypor
sdum.publicationstatusinfo:eu-repo/semantics/publishedVersionpor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
fimmu-07-00478.pdf
Tamanho:
3.89 MB
Formato:
Adobe Portable Document Format